title: Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
abstract: OBJECTIVE
  Lafutidine is a novel H(2)-receptor antagonist with gastroprotective activity that includes enhancement of gastric mucosal blood flow. The aim of the present study was to test the efficacy of 7- or 14-day lafutidine-clarithromycin-amoxicillin therapy versus a lansoprazole-based regimen for Helicobacter pylori eradication.
  
  
  METHODS
  Four hundred and sixty-three patients with H. pylori-infected peptic ulcer disease were randomized to one of four regimens: (1) lafutidine (20 mg b.i.d.), clarithromycin (500 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LFT group) or (2) for 14 days (the 14LFT group); (3) lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1000 mg b.i.d.) for 7 days (the 7LPZ group); or (4) for 14 days (the 14LPZ group). The eradication rates, drug compliance, and adverse effects among the four regimens were compared.
  
  
  RESULTS
  The eradication rates by the intention-to-treat and per-protocol analyses in the 7LFT and 7LPZ groups were 76.5% and 81.6%, and 76.9% and 82.0% (p = .94 and .95), respectively. The eradication rates by intention-to-treat and per-protocol analyses in the 14LFT and 14LPZ groups were 78.2% and 82.2%, and 80.4% and 85.9% (p = .70 and .49), respectively. The treatment duration for 7 days or 14 days did not affect the eradication rates. In addition, the adverse effect rates and discontinuation rates were similar among the four groups. Furthermore, the ulcer cure rate and symptom response rate were similar in the lafutidine and lansoprazole groups.
  
  
  CONCLUSIONS
  The results of this study showed that lafutidine-clarithromycin-amoxicillin therapy was a safe and effective as lansoprazole-based triple therapy for the eradication rate of H. pylori, and could be considered as an additional treatment option.
authors.affiliation: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
authors.forename: Nayoung
authors.initials: N
authors.lastname: Kim
authors.forename: Soo-Heon
authors.initials: SH
authors.lastname: Park
authors.forename: Geom Seog
authors.initials: GS
authors.lastname: Seo
authors.forename: Sang Woo
authors.initials: SW
authors.lastname: Lee
authors.forename: Jae Woo
authors.initials: JW
authors.lastname: Kim
authors.forename: Kwang Jae
authors.initials: KJ
authors.lastname: Lee
authors.forename: Won-Chang
authors.initials: WC
authors.lastname: Shin
authors.forename: Tae Nyeun
authors.initials: TN
authors.lastname: Kim
authors.forename: Moo-In
authors.initials: MI
authors.lastname: Park
authors.forename: Jong-Jae
authors.initials: JJ
authors.lastname: Park
authors.forename: Su Jin
authors.initials: SJ
authors.lastname: Hong
authors.forename: Ki-Nam
authors.initials: KN
authors.lastname: Shim
authors.forename: Sang Wook
authors.initials: SW
authors.lastname: Kim
authors.forename: Yong-Woon
authors.initials: YW
authors.lastname: Shin
authors.forename: Young-Woon
authors.initials: YW
authors.lastname: Chang
authors.forename: Hoon Jai
authors.initials: HJ
authors.lastname: Chun
authors.forename: Ok-Jae
authors.initials: OJ
authors.lastname: Lee
authors.forename: Won-Joong
authors.initials: WJ
authors.lastname: Jeon
authors.forename: Chan-Guk
authors.initials: CG
authors.lastname: Park
authors.forename: Chang-Min
authors.initials: CM
authors.lastname: Cho
authors.forename: Cheol Hee
authors.initials: CH
authors.lastname: Park
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Won
authors.forename: Gin Hyug
authors.initials: GH
authors.lastname: Lee
authors.forename: Kyung Sik
authors.initials: KS
authors.lastname: Park
authors.forename: Jeong Eun
authors.initials: JE
authors.lastname: Shin
authors.forename: Heung Up
authors.initials: HU
authors.lastname: Kim
authors.forename: Joon Yong
authors.initials: JY
authors.lastname: Park
authors.forename: Hiun Suk
authors.initials: HS
authors.lastname: Chae
authors.forename: Geun Am
authors.initials: GA
authors.lastname: Song
authors.forename: Jae Gyu
authors.initials: JG
authors.lastname: Kim
authors.forename: Byung Chul
authors.initials: BC
authors.lastname: Yoon
authors.forename: Sangyong
authors.initials: S
authors.lastname: Seol
authors.forename: Hyun Chae
authors.initials: HC
authors.lastname: Jung
authors.forename: In-Sik
authors.initials: IS
authors.lastname: Chung
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000081:Acetamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007723:Korea; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000081:Acetamides; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D010880:Piperidines; D011725:Pyridines; D064747:Lansoprazole; C076948:lafutidine; D000658:Amoxicillin; D017291:Clarithromycin